Allogeneic HCT outcomes in adults 70 years and older. (A) OS after HCT in patients ≥70 years by year of transplant (2000-2007 vs 2008-2013). (B) Disease-free survival after HCT in patients ≥70 years with AML in remission, myelodysplasia, and chemotherapy-sensitive NHL from 2008 to 2013. (C) OS after HCT in patients ≥70 years with AML in remission, myelodysplasia, and chemotherapy-sensitive NHL from 2008 to 2013. (D) Disease-free survival after HCT in patients ≥70 years from 2008 to 2013 according to DRI. (E) OS after HCT in patients ≥70 years from 2008 to 2013 according to DRI.